{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:17:02Z","timestamp":1788895022365,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the cycle characteristics and pregnancy outcomes of progestin-primed ovarian stimulation (PPOS) using fixed versus degressive doses of medroxyprogesterone acetate (MPA) in conjunction with letrozole (LE) in infertile women by propensity score matching (PSM) analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Tertiary-care academic medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Population<\/jats:title><jats:p>A total of 3173 infertile women undergoing their first <jats:italic>in vitro<\/jats:italic> fertilization\/intracytoplasmic sperm injection (IVF\/ICSI) treatment within the period from January 2017 to December 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 1068 and 783 patients who underwent a fixed dose of MPA combined with LE and a degressive dose of MPA combined with LE protocols, respectively, were enrolled in this study. The freeze-all approach and later frozen-thawed embryo transfer (FET) were performed in both groups. Propensity score matching (1:1) was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>The primary outcomes were the dosage of MPA and the incidence of premature luteinizing hormone (LH) surges. The secondary outcomes were the number of oocytes retrieved, the cumulative live birth rate (CLBR) and the fetal malformation rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We created a perfect match of 478 patients in each group. The dosage of MPA, the LH serum level on the eighth day of stimulation, progesterone (P) level and LH level on the hCG trigger day were significantly higher in the LE + fixed MPA group than in the LE + degressive MPA group (52.1 \u00b1 13.1 mg vs. 44.9 \u00b1 12.5 mg; 5.0 \u00b1 2.7 IU\/L vs. 3.7 \u00b1 1.7 IU\/L; 0.9 \u00b1 0.5 ng\/ml vs. 0.8 \u00b1 0.5 ng\/ml; 3.3 \u00b1 2.4 IU\/L vs. 2.8 \u00b1 1.9 IU\/L; <jats:italic>P<\/jats:italic> &amp;lt; 0.01). The duration of Gn, the number of follicles with diameter more than 16\u00a0mm on trigger day, the estradiol (E<jats:sub>2<\/jats:sub>) level on the hCG trigger day were lower in the LE + fixed MPA group than in the LE + degressive MPA group (9.7 \u00b1 1.7 days vs. 10.3 \u00b1 1.5 days; 5.6 \u00b1 3.0 vs. 6.3 \u00b1 3.0; 1752.5 \u00b1 1120.8 pg\/ml vs. 1997.2 \u00b1 1108.5 pg\/ml; <jats:italic>P<\/jats:italic> &amp;lt; 0.001). No significant difference was found in the incidence of premature LH surge, the number of oocytes retrieved, the number of top-quality embryos, clinical pregnancy rate (CPR), CLBR or fetal malformation rate between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of a degressive MPA dose with LE proved effective in reducing the total MPA dosage with comparable premature LH surge and pregnancy outcomes in women undergoing the PPOS protocol.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1295787","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:35:49Z","timestamp":1702395349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: a propensity score-matched study"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nongqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglu","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.702558","article-title":"Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: A meta-analysis of randomized controlled trials","volume":"12","author":"Guan","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05939-y","article-title":"Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis","volume":"303","author":"Cui","year":"2021","journal-title":"Arch Gynecol Obstet."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708704","article-title":"Comparison of dydrogesterone and medroxyprogesterone in the progestin-primed ovarian stimulation protocol for patients with poor ovarian response","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s13063-018-2850-x","article-title":"Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial","volume":"19","author":"Wang","year":"2018","journal-title":"Trials."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.797227","article-title":"The comparison of fixed and flexible progestin primed ovarian stimulation on mature oocyte yield in women at risk of premature ovarian insufficiency","volume":"12","author":"Kalafat","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.705264","article-title":"Comparison of the cumulative live birth rates of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols in patients with low prognosis","volume":"12","author":"Du","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-018-0335-0","article-title":"An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders","volume":"16","author":"Huang","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00696","article-title":"A higher estradiol rise after dual trigger in progestin-primed ovarian stimulation is associated with a lower oocyte and mature oocyte yield in normal responders","volume":"10","author":"Huang","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.repbio.2021.100540","article-title":"A comprehensive evaluation of progestin-primed ovarian stimulation protocol in patients with or without PCOS undergoing in vitro fertilization","volume":"21","author":"Zhu","year":"2021","journal-title":"Reprod Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409154654","article-title":"The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses","volume":"63","author":"Wikstr\u00f6m","year":"1984","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14622","article-title":"The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial","volume":"124","author":"Dong","year":"2017","journal-title":"BJOG."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.965210","article-title":"Letrozole cotreatment with progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing IVF treatment","volume":"13","author":"Liu","year":"2022","journal-title":"Front Physiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13567","article-title":"Progestin-primed ovarian stimulation protocol with or without letrozole for patients with normal ovarian reserve: a retrospective cohort study","volume":"47","author":"Jiang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420220302","article-title":"Congenital abnormalities and hormones during pregnancy: a\u00a0clinical review","volume":"22","author":"Schardein","year":"1980","journal-title":"Teratology."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(16)46823-8","article-title":"Teratogenic effects of Silastic intrauterine devices in the\u00a0rat with or without added medroxyprogesterone acetate","volume":"39","author":"Barlow","year":"1983","journal-title":"Fertil Steril."},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/tera.1420150104","article-title":"Prenatal toxicity of medroxyprogesterone acetate in rabbits, rats, and mice","volume":"15","author":"Andrew","year":"1977","journal-title":"Teratology."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(69)90528-6","article-title":"Simulated congenital adrenal hyperplasia in a male neonate associated with medroxyprogesterone therapy during pregnancy","volume":"103","author":"Limbeck","year":"1969","journal-title":"Am J Obstet Gynecol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1056\/nejm197701132960202","article-title":"Cardiovascular birth\u00a0defects and antenatal exposure to female sex hormones","volume":"296","author":"Heinonen","year":"1977","journal-title":"N Engl J Med"},{"key":"B20","volume-title":"NTP research reports. NTP research report on the scoping review of prenatal exposure to progestogens and adverse health outcomes: research report 17","year":"2020"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.05.078","article-title":"A new era in ovulation induction","volume":"85","author":"Holzer","year":"2006","journal-title":"Fertil Steril."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666170-00001","article-title":"Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women","volume":"66","author":"Mitwally","year":"2006","journal-title":"DRUGS."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmn033","article-title":"Use of letrozole in assisted reproduction: a systematic review and meta-analysis","volume":"14","author":"Requena","year":"2008","journal-title":"Hum Reprod Update."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1072170","article-title":"Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2020.07.003","article-title":"Pregnancy rates from intrauterine insemination are equivalent following 1- versus 5-day letrozole administration for ovulation induction: a retrospective study","volume":"1","author":"McGrail","year":"2020","journal-title":"F S Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.07.952","article-title":"Single-dose administration of an aromatase inhibitor\u00a0for ovarian stimulation","volume":"83","author":"Mitwally","year":"2005","journal-title":"Fertil Steril."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409154654","article-title":"The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses","volume":"63","author":"Wikstr\u00f6m","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.690575","article-title":"Fixed gonadotropin-releasing hormone antagonist protocol versus flexible progestin-primed ovarian stimulation protocol in patients with asynchronous follicular development during controlled ovulation stimulation: a retrospective study","volume":"12","author":"Dong","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez034","article-title":"Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial","volume":"34","author":"Beguer\u00eda","year":"2019","journal-title":"Hum Reprod"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez034","article-title":"Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles","volume":"37","author":"Ozgur","year":"2020","journal-title":"J\u00a0Assist Reprod Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.06.009","article-title":"Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology","volume":"112","author":"Yildiz","year":"2019","journal-title":"Fertil Steril."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14647273.2020.1794060","article-title":"Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve","volume":"25","author":"Turkgeldi","year":"2020","journal-title":"Hum Fertil (Camb)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.837880","article-title":"Outcomes of a gnRH agonist trigger following a GnRH antagonist or flexible progestin-primed ovarian stimulation cycle","volume":"13","author":"Kalafat","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1986.tb00115.x","article-title":"Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation","volume":"58","author":"Johansson","year":"1986","journal-title":"Acta Pharmacol Toxicol (Copenh)."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/00016349409013457","article-title":"Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease","volume":"73","author":"Anttila","year":"1994","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13835","DOI":"10.1038\/s41598-018-32128-4","article-title":"Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles","volume":"8","author":"Sun","year":"2018","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802374815","article-title":"Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in\u00a0anovulatory women with LH and FSH deficiency: evidence of a threshold effect","volume":"24","author":"O'Dea","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/rep.0.1230023","article-title":"Survival factors regulating ovarian apoptosis \u2013 dependence on follicle differentiation","volume":"123","author":"Markstr\u00f6m","year":"2002","journal-title":"Reproduction"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1113840","article-title":"Role of luteinizing hormone elevation in outcomes of ovulation induction with letrozole for polycystic ovary syndrome","volume":"10","author":"Fu","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.744968","article-title":"Luteinizing hormone suppression by progestin-primed ovarian stimulation is associated with higher implantation rate for patients with polycystic ovary syndrome who underwent in vitro fertilization\/intracytoplasmic sperm injection cycles: comparing with short protocol","volume":"12","author":"Chen","year":"2021","journal-title":"Front Physiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12958-018-0373-7","article-title":"Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome","volume":"16","author":"Ye","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S230129","article-title":"Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: a Retrospective Cohort Study","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2939","DOI":"10.1097\/md.0000000000002939","article-title":"Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial","volume":"95","author":"Wang","year":"2016","journal-title":"Med (Baltimore)."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.02.036","article-title":"Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial","volume":"116","author":"Giles","year":"2021","journal-title":"Fertil Steril."},{"key":"B45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.21037\/atm.2020.02.15","article-title":"Impacts of medroxyprogesterone acetate on oocytes and embryos: matched case-control study in women with stage III-IV ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"8","author":"Guo","year":"2020","journal-title":"Ann Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11927","DOI":"10.1038\/s41598-017-12151-7","article-title":"Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"7","author":"Guo","year":"2017","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.938500","article-title":"Analysis of cumulative live birth rate and perinatal outcomes in young patients with low anti-m\u00fcllerian hormone levels using two ovulation promotion protocols: A cohort study","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00796","article-title":"Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial","volume":"10","author":"Chen","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05065-4","article-title":"Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization\/intracytoplasmic sperm injection: an analysis of 1188 cycles","volume":"299","author":"Guo","year":"2019","journal-title":"Arch Gynecol Obstet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jfma.2022.08.023","article-title":"Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval","volume":"122","author":"Kao","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-020-01755-0","article-title":"Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysis","volume":"37","author":"Zolfaroli","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S263138","article-title":"Live-birth outcomes and congenital malformations after progestin-primed ovarian stimulation in maternal endometriosis","volume":"14","author":"Liang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4537-z","article-title":"Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles","volume":"296","author":"Zhang","year":"2017","journal-title":"Arch Gynecol Obstet."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1295787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:35:53Z","timestamp":1702395353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1295787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":53,"alternative-id":["10.3389\/fendo.2023.1295787"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1295787","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"article-number":"1295787"}}